Zinbryta® (daclizumab)

Zinbryta was a prescription medicine manufactured by Biogen, Inc. that was used to treat of adults with relapsing multiple sclerosis (MS). It was pulled from all markets (US and global) in March of 2018 due to safety concerns.

How does Zinbryta work?

While the exact mechanism of action of Zinbryta is not fully understood, Zinbryta is a laboratory-created monoclonal antibody that targets the CD25 receptor where a key immune signaling chemical called interleukin-2 (IL-2). IL-2 is abnormally activated in MS and signals the T-cells that are involved in MS attacks. By blocking this receptor, Zinbryta inhibits some of the inflammatory actions of T-cells.1,2

Are there people who should not take Zinbryta?

Zinbryta is no longer an available treatment for multiple sclerosis.

What are the side effects that Zinbryta may cause?

Zinbryta may cause serious side effects, including liver problems and immune system problems. 1

Written by: Jonathan Simmons & Kristine Zerkowski| Last reviewed: April 2018.
View References